Obeticholic acid: A rising star in the treatment of liver disease, but use with caution

Obeticholic acid (Obeticholic acid), this innovative drug has attracted much attention from the medical community in recent years. However, although it has attracted widespread attention globally, unfortunately, it has not yet been approved for marketing in China, so domestic liver disease patients are still unable to benefit from this new therapy.

Obeticholic acid regulates the anabolic pathway of bile acids in the liver through a unique mechanism of action, thereby optimizing the metabolic function of the liver. Multiple global clinical trials have confirmed that the drug has significant efficacy in reducing liver inflammation, mitigating fibrosis, and improving liver function. In addition to showing potential in the treatment of various liver diseases such as primary biliary cirrhosis (PBC), obeticholic acid also has multiple effects such as anti-cholestasis, anti-inflammation, anti-fibrosis and promotion of cell proliferation.

However, despite its promising results in treating liver disease, obeticholic acid is not suitable for all patients with liver disease. Particularly in the United States, the Food and Drug Administration (FDA) has imposed restrictions on the use of obeticholic acid. For patients with advanced cirrhosis and primary biliary cholangitis (PBC), the use of obeticholic acid may pose serious health risks. In fact, some patients have developed serious complications such as liver failure after using this drug, and even required liver transplantation.

In view of this,FDA has added contraindications to obeticholic acid’s prescribing information and medication guidelines, explicitly prohibiting the use of this drug in patients with advanced cirrhosis of PBC. This initiative is designed to protect patients from potential health hazards and ensure that medicines are used safely and effectively in appropriate patient groups. Obeticholic acid remains a treatment with significant benefit for patients with PBC who do not develop advanced cirrhosis.